RxDoctor Payments Data

Salman Azam, MD

Interventional Cardiology · Torrance, CANPI 1962616888

Payments from drug & device makers

$199,924in general payments, 2019–2025

Across 646 payments — averaging $309.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$190K
  • Boston Scientific$3K
  • Abbott$2K
  • Medtronic$2K
  • Novartis$598
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$551
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$170,10085%
  • Speaking & faculty fees$5,5003%
  • Travel & lodging$9,4265%
  • Food & beverage$14,8927%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$199,924 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$214,090
Medicare patients
897
Services billed
2,523

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban212$267,922
EntrestoSacubitril/Valsartan90$114,576
XareltoRivaroxaban93$108,228
JardianceEmpagliflozin40$52,342
Repatha SureclickEvolocumab39$36,753
BrilintaTicagrelor19$15,189
Icosapent Ethyl14$7,732
Metoprolol Succinate290$4,696
Carvedilol365$3,692
Atorvastatin Calcium290$2,839
Isosorbide Mononitrate ErIsosorbide Mononitrate151$2,831
ClopidogrelClopidogrel Bisulfate167$1,885
Furosemide242$1,437
Losartan Potassium100$1,212
Ranolazine ErRanolazine11$1,193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$437$267,922212 claims
NovartisEntresto$598$114,57690 claims
Johnson & JohnsonXarelto$495$108,22893 claims
Boehringer IngelheimJardiance$191$52,34240 claims
AstraZenecaBrilinta$68$15,18919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →